Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination

Clinical Transplantation

Volumn 12, Issue 2, 1998, Pages 90-98

  Carlens, Stefan ^a   Ringdén, Olle ^a   Aschan, Johan ^a   Hägglund, Hans ^a   Ljungman, Per ^a   Mattsson, Jonas ^a   Remberger, Mats ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bone marrow transplantation; Ciprofloxacin; Graft vs. host disease; Leukemia; Relapse; Riskfactors

Indexed keywords

BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; METHOTREXATE; ANTIINFECTIVE AGENT; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHILD; FEMALE; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE INFECTION; HERPES VIRUS; HLA MATCHING; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; SURGICAL MORTALITY; WHOLE BODY RADIATION; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; HERPES VIRUS INFECTION; HISTOCOMPATIBILITY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MORTALITY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RETROSPECTIVE STUDY;

ADULT; ANTI-INFECTIVE AGENTS; BONE MARROW TRANSPLANTATION; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HERPESVIRIDAE INFECTIONS; HISTOCOMPATIBILITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION CONDITIONING;

EID: 0032043736     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. THOMAS ED, STORB R, CLIFT RA, et al. Bone marrow transplantation 1 and II. N Engl J Med 1975: 292: 832 and 895.
2. APPELBAUM FR, FISHER LD, THOMAS ED, The Seattle Marrow Transplant Team. Chemotherapy vs. marrow transplantation for adults with acute nonlymphocytic leukaemia: A five-year follow-up. Blood 1988: 72: 179.
3. BARRETT AJ, HOROWITZ MM, GALE RR. Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival. Blood 1989: 74: 862.
4. RINGDÉN O, ZWAAN FE, HERMANS J, GRATWOHL A, for the Leukemia Working Party of The European Group for Bone Marrow Transplantation. European experience of bone marrow transplantation for leukemia. Transpl Proc 1987: 19: 2600.
5. GIRALT SA, CHAMPLIN RE. Leukemia relapse after allogeneic bone marrow transplantation: A review. Blood 1994: 84 (11): 3603.
6. CLIFT RA, BUCKNER CD, APPELBAUM FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia m first remission: A randomized trial of two irradiation regimens. Blood 1990: 76: 1867.
7. GOLDMAN JM, GALE RP, HOROWITZ MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk of relapse associated with T-22. cell depletion. Ann Int Med 1988: 108: 806.
8. ASCHAN J, RINGDEN O, SUNDERG B, GAHRTON G, LJUNGMAN P, WINIARSKI J. Methotrexate combined with cyclosporine A decreases graft vs. host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transpl 1991: 7: 113.
9. WEAVER CH, HANSEN JA, MARTIN PO, et al. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. Bone Marrow Transpl 1994: 14 (6): 885.
10. WEIDEN PL, SULLIVAN KM, FLOURNOY N, STORB R, THOMAS ED, the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981: 304: 1529.
11. HOROWITZ MM, GALE RP, SONDEL PM, et al. Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood 1989: 175: 555.
12. STORB R, DEEG HJ, PEPE M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989: 73: 1729.
13. RINGDÉN O, HOROWITZ MM, SONDEL P, et al. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993: 81: 1094.
14. GALE RP, HOROWITZ MM, WEINER RS, et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukaemia in first remission. Bone Marrow Transpl 1995: 16: 203.
15. RINGDÉN O, REMBERGER M, PERSSON U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA identical siblings Bone Marrow Transpl 1995: 15: 619.
16. RINGDÉN O, BÄRYD I, JOHANSSON B, et al. Increased mortality by septicemia, interstitial pneumonitis and pulmonary fibrosis among bone marrow transplant recipients receiving an increased mean dose rate of total irradiation. Acta Radiol Oncol 1983: 22: 423.
17. RINGDÉN O, REMBERGER M, ASCHAN J, LJUNGMAN P, LÖNNQVIST B, MARKLING L. Long-term follow-up of a randomized trial comparing T-cell-depletion with a combination of methotrexate and cyclosporin in adult leukemic marrow transplant recipients. Transplantation 1994: 58: 887.
18. RINGDÉN O, RUUTU T. REMBERGER M, et al for the Nordic Bone Marrow Transplantation Group. A randomized trial comparing busulphan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia. A report from the Nordic Bone Marrow Transplantation Group. Blood 1994: 83: 2723.
19. STORB R, EPSTEIN RB, GRAHAM TC, THOMAS ED. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970: 9: 240.
20. RINGDÉN O, BACKMAN L, LONNQVIST B, et al. A randomized trial comparing the use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematologic malignancies. Bone Marrow Transpl 1986: 1: 41.
21. ASCHAN J, RINGDÉN O, ANDSTRÖM E, LJUNGMAN P, LONNQVIST B, REMBERGER M. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients. Bone Marrow Transpl 1994: 14: 79.
22. BOSTRÖM L, RINGDÉN O, GRATAMA JW, et al. For the Leukaemia Working Party of The European Group for Bone Marrow Transplantation. A role of herpes virus serology for the development of acute graft-versus-host disease. Bone Marrow Transpl 1990: 5: 321.
23. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972: 34: 187.
24. KAPLAN EI, MEIER P. Non-parametric estimation for incomplete observations. J Am Stat Assoc 1958: 53: 457.
25. ENTERLINE PK. Pitfalls in epidemiological research; an examination of asbestos literature. J Occup Med 1976: 18: 150.
26. GALE RP, BORTIN MM, VAN BEKKUM DM, et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987: 67: 397.
27. MEYERS JD, FLOURNOY N, THOMAS ED. Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant. J Infect Dis 1980: 142: 816.
28. PAULIN T, RINGDÉN O, LONNQVIST B, WAHREN B, NILSSON B. The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection An analysis of risk factors Scand J Infect Dis 1986: 18: 199.
29. KERNAN NA, BORDIGNOR C, KEEVER CA, et al. Graft failure after T-cell-depleted marrow transplants for leukemia: clinical and in vitro characteristics. Transpl Proc 1987: 19 (suppl 7): 29.
30. HOWS J, BRADLEY BA, GORE S, DOWNIE T, HOWARD M, GLUCKMAN E, on behalf of the International Marrow Unrelated Search Transplant (IMUST) Study Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transpl 1993: 12: 371.
31. MARKS DI, CULLIS JO, WARD KN, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. Ann Intern Med 1993: 119: 207.
32. BLAISE D, MARANINCHI D, ARCHIMBAUD E, et al. Allogeneic bone marrow transplantation for acute myeloid leukaemia in first remission: A randomized trial of busulfancytoxan versus cytoxan-total body irradiation as preparative regimen: A report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood 1992: 79: 2578.
33. RINGDÉN O, LABOPIN M, MANDELLI F, et al. for the Acute Leukemia Working Party of the EBMT. A comparison of busulfan vs. total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Br J Hematol 1996: 93: 637.
34. GRATWOHL A, HERMANS J, APPERLEY J, et al. For the Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation Acute graft-versushost disease: Grade and outcome in patients with chronic myelogenous leukemia. Blood 1995: 86(2): 8i3.
35. RINGDÉN O, HERMANS J, LABOPIN M, APPERLEY J. GORIN NC, GRATWOHL A, for the Acute and Chronic Leukemia Working Parties Of the European Group For Blood And Marrow Transplantation (EBMT). The highest leukemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Leukemia & Lymphoma 1996: 24: 71.